At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Memory Advancement by Intranasal Insulin in Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating Regular Human Insulin and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 289 participants across 2 sites.
Detailed Summary
The main purpose of this study is to find the long-term effects of daily administration of 40 IU of intranasal insulin (INI) as compared to placebo (sterile saline) on cognition and memory in people with type 2 diabetes mellitus (DM), and non-diabetic controls over 24 weeks with a follow-up period for 24 weeks. Four groups will be tested: DM group treated with INI; DM group treated with placebo; control group treated with INI and the control group treated with placebo. The INI or placebo will be delivered into the nose. The investigators are interested to see whether INI can improve memory and cognition and blood flow in the brain in the type 2 DM group as compared to placebo and to the non-diabetic group over a long-term period.
Study Details
Timeline
Interventions
Regular human insulin 40 IU daily over 24 weeks
Intranasal sterile saline 40 IU daily over 24 weeks